Physician profile

Steven E Georgeson

Cardiovascular Disease · Bridgewater, NJ

NPI 1487627741

$3,646.56

in general payments reported to CMS, 2019-2025

32 companies · $634 in 2025

The $634 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,812.82

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pfizer INC. $491.68 2019-2025
Novartis Pharmaceuticals Corporation $402.84 2019-2025
Amgen INC. $396.88 2019-2025 Repatha, Repatha
Boston Scientific Corporation $395.55 2022-2024 Watchman Access System, Watchman Flx, Watchman
Boehringer Ingelheim Pharmaceuticals, INC. $231.97 2022-2025 Jardiance
E.R. Squibb & Sons, L.L.C. $228.04 2019-2025 Camzyos
Edwards Lifesciences Corporation $159.19 2024-2025 Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Abiomed $158.90 2023-2025 Impella
Janssen Pharmaceuticals, INC $142.02 2019-2024 Xarelto
Abbott Laboratories $122.27 2019-2025 Aveir, Amplatzer Amulet
Merck Sharp & Dohme LLC $113.33 2021-2025 Verquvo
Esperion Therapeutics, INC. $111.92 2021-2025 Nexletol
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $85.90 2023-2025 Lifevest
Alnylam Pharmaceuticals INC. $85.51 2023-2025 Onpattro
Amarin Pharma, INC. $82.81 2019-2022
Show all 31 companies
CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $61.82 2020-2024 Farxiga
Sanofi-Aventis U.S. LLC $47.74 2019-2023
Cvrx, INC. $46.52 2025 Barostim Neo System
Kowa Pharmaceuticals America, INC. $40.14 2020-2021
Scpharmaceuticals INC. $36.98 2024-2025
Bard Peripheral Vascular, INC. $30.57 2024 Venclose Maven Catheter
Arbor Pharmaceuticals, INC. $27.82 2019-2021
Atricure, INC. $21.46 2024
Bayer Healthcare Pharmaceuticals INC. $17.73 2025
Biosense Webster, INC. $17.64 2025 Carto 3
Medtronic, INC. $17.26 2021
Daiichi Sankyo INC. $14.99 2022
Lundbeck LLC $14.97 2019
Kiniksa Pharmaceuticals International, Plc $14.40 2024 Arcalyst
Kiniksa Pharmaceuticals, LTD. $14.29 2023 Arcalyst
Regeneron Healthcare Solutions, INC. $13.42 2019

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Steven E Georgeson

$3,646.56

in general payments reported 2019-2025

Years
2019-2025
Top company
Pfizer INC.
Context
The $634 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/248253/steven-e-georgeson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.